Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 221-227 , May 2007

Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway

Received 1 February 2006 ,Revised 28 June 2006 ,Accepted 14 July 2006.

References 

  1. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964–969
  2. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer. 2004;91:607–612
  3. Chen F, Zhang G, Iwamoto Y, et al. Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking alpha 5 beta 1 integrin. J Urol. 2003;170:605–610
  4. Chen FH, Crist SA, Zhang GJ, et al. Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. J Urol. 2002;168:786–797
  5. Pryor K, Stricker P, Russell P, et al. Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. Cancer Immunol Immunother. 1995;41:309–316
  6. Seow SW, Rahmat JN, Mohamed AA, et al. Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis (bacillus Calmette-Guerin). J Urol. 2002;168:2236–2239
  7. Chen F, Zhang G, Iwamoto Y, et al. BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol. 2005;5:8
  8. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825
  9. Toneguzzo F, Glynn S, Levi E, et al. Use of a chemically modified T7 DNA polymerase for manual and automated sequencing of supercoiled DNA. Biotechniques. 1988;6:460–469
  10. Cooper MJ, Haluschak JJ, Johnson D, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res. 1994;6:569–579
  11. Dirks PB, Rutka JT. Current concepts in neuro-oncology: The cell cycle–A review. Neurosurgery. 1997;40:1000–1013
  12. Smith KJ, Barrett TL, Smith WF, et al. A review of tumor suppressor genes in cutaneous neoplasms with emphasis on cell cycle regulators. Am J Dermatopathol. 1998;20:302–313
  13. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature. 1993;366:701–704
  14. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805–816
  15. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 1999;246:280–289
  16. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90:1072–1079
  17. Wolf HK, Stober C, Hohenfellner R, et al. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol. 2001;22:328–336
  18. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: The role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol. 2004;45:606–612
  19. Rotterud R, Berner A, Holm R, et al. p53, p21 and mdm2 expression vs. the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int. 2001;88:202–208
  20. Flamm M, Brodowicz T, Haitel A, et al. Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. Anticancer Res. 2002;22:1295–1300
  21. Fontana D, Bellina M, Galietti F, et al. Intravesical bacillus calmette-guerin (BCG) as inducer of tumor-suppressing proteins p53 and p21 Waf1-Cip1 during treatment of superficial bladder cancer. J Urol. 1999;162:225–230
  22. Pfister C, Flaman JM, Dunet F, et al. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. J Urol. 1999;162:69–73
  23. Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol. 1999;161:792–798
  24. Makri D, Schulz WA, Grimm M, et al. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Int J Oncol. 1998;12:621–628
  25. Hall MC, Li Y, Pong RC, et al. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J Urol. 2000;163:1033–1038

☆ This work was supported by a grant from the Department of Veterans Affairs and the Milwaukee Veterans Affairs Medical Center.

PII: S1078-1439(06)00243-2

doi: 10.1016/j.urolonc.2006.07.021

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 3 , Pages 221-227 , May 2007

Article Tools

* Image Usage & Resolution